Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
In patients with acute hypoxemic respiratory failure secondary to COVID-19, are outcomes better with higher steroid dosing or different oxygenation strategies?
Bottom line
Administering high-dose vs standard-dose dexamethasone does not affect 60-day mortality in critically ill patients with AHRF due to severe COVID-19. Further, in a subset of patients who do not require initial IMV, using CPAP versus HFNC versus standard oxygen therapy does not reduce the need for IMV at 28 days. 1b
Reference
Study design: Randomized controlled trial (nonblinded)
Funding: Government
Setting: Inpatient (ICU only)
Synopsis
In this multicenter study from France, adults admitted to an intensive care unit with acute hypoxemic respiratory failure (AHRF) secondary to COVID-19 were randomized to receive standard dexamethasone phosphate at 6 mg per day for days 1 to 10 (n = 276) or high-dose dexamethasone phosphate at 20 mg per day for days 1 to 5 followed by 10 mg per day for days 6 to 10 (n = 270). All patients were also given matching placebo. Patients who did not require invasive mechanical ventilation (IMV) were then further randomized to receive oxygenation with intermittent continuous positive airway pressure (CPAP), high-flow nasal cannula oxygen (HFNC) at 30 L per minute and increased up to 60 L per minute, or standard oxygen therapy. In all 3 groups, oxygen flow was adjusted for a target oxygen saturation of 92% or greater. Overall, 17% of patients did not adhere to their allocated oxygenation strategy. For the primary outcome of the steroid intervention, there was no significant difference in 60-day mortality (26.8% for the high dose vs 25.9% for the standard dose; hazard ratio 0.96; 95% CI 0.69 - 1.33). This remained true regardless of IMV status. For the primary outcome when comparing the 3 oxygenation strategies, there was no significant difference in criteria to start IMV (worsening respiratory failure, hemodynamic instability, and neurological status deterioration) at 28 days (43.0% with CPAP and 43.8% with HFNC vs 41.4% with standard oxygen). Adverse events were similar in all intervention groups.
Reviewer
Nita Shrikant Kulkarni, MD
Assistant Professor in Hospital Medicine
Northwestern University
Chicago, IL
Comments
Interesting
Covid continues to confound modern medicine. Hope the Omicron vaccine helps take care of it.
hd cirticosteroid use i n rf
no benefit